Onco-cardiology and cardiovascular toxicity
Research activity at Semmelweis University Heart and Vascular Centre in Budapest is centred on the cardiovascular effects of immune checkpoint inhibitors used in cancer care, with attention to cardiac and vascular complications arising during treatment.
- Cardiovascular side effects of immune checkpoint inhibitors
- Cardiac monitoring in oncology patients
- Vascular complications linked to cancer immunotherapy
The clinical focus connects cardiology with oncology in the assessment of treatment-related cardiovascular risk.
Immuno-oncology in solid tumours
The sponsor’s trial portfolio includes cancers treated with immune checkpoint blockade, reflecting interest in malignancies commonly managed with modern immunotherapy.
- Malignant melanoma
- Non small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
These disease areas place emphasis on the interaction between systemic cancer therapy and cardiovascular health.
Urologic oncology
Clinical interest extends to genitourinary cancers, with research relevant to patients receiving immunotherapy for bladder carcinoma and renal cell carcinoma.
- Bladder carcinoma
- Renal cell carcinoma
This area supports evaluation of treatment-related cardiovascular considerations in urologic malignancies.
Head and neck oncology
The sponsor also funds research relevant to tumors of the head and neck region, a cancer group frequently treated with immunotherapeutic approaches that require careful cardiovascular observation.
- Head and neck tumors
- Therapy-related cardiovascular surveillance
This work aligns with the broader clinical interest in managing oncology-related cardiovascular risk across multiple tumour types.
